Phase 1a of the trial examined dose escalation of IO-202 as a monotherapy and in combination with azacitidine. Phase 1b of ...
At the 2025 North American Neuroendocrine Tumor Society (NANETS) Multidisciplinary NET Medical Symposium, Alexa Meara, MD, explored the interface of oncology and rheumatology in the immunotoxicity ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback